These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31604991)

  • 1. The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway.
    Gul N; Karlsson J; Tängemo C; Linsefors S; Tuyizere S; Perkins R; Ala C; Zou Z; Larsson E; Bergö MO; Lindahl P
    Sci Rep; 2019 Oct; 9(1):14667. PubMed ID: 31604991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.
    Patterson JC; Joughin BA; Prota AE; Mühlethaler T; Jonas OH; Whitman MA; Varmeh S; Chen S; Balk SP; Steinmetz MO; Lauffenburger DA; Yaffe MB
    Cell Syst; 2019 Jul; 9(1):74-92.e8. PubMed ID: 31302152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.
    Rudd SG; Gad H; Sanjiv K; Amaral N; Hagenkort A; Groth P; Ström CE; Mortusewicz O; Berglund UW; Helleday T
    Cancer Res; 2020 Sep; 80(17):3530-3541. PubMed ID: 32312836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures.
    van der Waals LM; Laoukili J; Jongen JMJ; Raats DA; Borel Rinkes IHM; Kranenburg O
    Sci Rep; 2019 Jan; 9(1):819. PubMed ID: 30692572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
    BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
    Aristizabal Prada ET; Orth M; Nölting S; Spöttl G; Maurer J; Auernhammer C
    PLoS One; 2017; 12(5):e0178375. PubMed ID: 28542590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
    Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
    EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of residue in the position of 116 on the inhibitory potency of TH588 for MTH1.
    Niu RJ; Zheng QC; Zhang HX
    J Mol Graph Model; 2018 Oct; 85():75-83. PubMed ID: 30103119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.
    Meitinger F; Anzola JV; Kaulich M; Richardson A; Stender JD; Benner C; Glass CK; Dowdy SF; Desai A; Shiau AK; Oegema K
    J Cell Biol; 2016 Jul; 214(2):155-66. PubMed ID: 27432897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proliferation-Inhibitory and Apoptosis-Inducing Effects of Targeting MTH1 on Multiple Myeloma Cells].
    Wang X; Wu Y; Zhang L; Li YX; Han B; Shi X; Wang W; Wang LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1598-1604. PubMed ID: 33067960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
    Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
    Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
    Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
    Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
    Oksvold MP; Berglund UW; Gad H; Bai B; Stokke T; Rein ID; Pham T; Sanjiv K; Øy GF; Norum JH; Smeland EB; Myklebust JH; Helleday T; Våtsveen TK
    Sci Rep; 2021 Mar; 11(1):6317. PubMed ID: 33737576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TH588 and Low-Dose Nocodazole Impair Chromosome Congression by Suppressing Microtubule Turnover within the Mitotic Spindle.
    Rajendraprasad G; Eibes S; Boldú CG; Barisic M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of MutT homolog 1 inhibitors in human bladder cancer cells.
    Lee JW; Lee S; Ho JN; Youn JI; Byun SS; Lee E
    Biosci Biotechnol Biochem; 2019 Dec; 83(12):2265-2271. PubMed ID: 31362565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and specific MTH1 inhibitors targeting gastric cancer.
    Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
    Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
    Shi XL; Li Y; Zhao LM; Su LW; Ding G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1.
    Wang M; Zhou S; Chen Q; Wang L; Liang Z; Wang J
    Sci Rep; 2017 Jan; 7():40557. PubMed ID: 28074893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.